Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

4.96USD
9:00pm BST
Change (% chg)

$-0.24 (-4.62%)
Prev Close
$5.20
Open
$4.84
Day's High
$5.20
Day's Low
$4.56
Volume
162,526
Avg. Vol
124,527
52-wk High
$111.30
52-wk Low
$4.12

Latest Key Developments (Source: Significant Developments)

Contravir Pharmaceuticals Gets Positive FDA Response To CRV431 Pre-Ind Package For NASH
Thursday, 20 Jun 2019 

June 20 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS RECEIVES POSITIVE FDA RESPONSE TO CRV431 PRE-IND PACKAGE FOR NASH.CONTRAVIR PHARMACEUTICALS - FDA CONCURRED WITH COMPANY'S PROPOSED PLAN FOR FURTHER PRECLINICAL STUDIES TO SUPPORT DEVELOPMENT OF CRV431.CONTRAVIR PHARMACEUTICALS INC - FDA SUPPORTED CONTRAVIR'S CLINICAL DEVELOPMENT PLANS FOR CRV431 IN NASH INDICATION.CONTRAVIR - FDA PROVIDED POSITIVE FEEDBACK ON CONTRAVIR'S EXISTING PRECLINICAL DATA OF CRV431 AND SUPPORTS STUDY DESIGN FOR NASH IND OPENING STUDY.  Full Article

Compelling Positive Results Reported From Human Liver Experiments With ContraVir Pharmaceuticals' NASH Drug Candidate
Monday, 17 Jun 2019 

June 17 (Reuters) - ContraVir Pharmaceuticals Inc ::COMPELLING POSITIVE RESULTS REPORTED FROM HUMAN LIVER EXPERIMENTS WITH CONTRAVIR PHARMACEUTICALS’ NASH DRUG CANDIDATE.CONTRAVIR PHARMACEUTICALS INC - ANNOUNCED FINDINGS FROM ITS FIRST STUDY WITH HUMAN PRECISION CUT LIVER SLICE CULTURES.CONTRAVIR PHARMACEUTICALS - LIVER DISEASE WAS SIMULATED IN EXPERIMENTAL MODEL BY APPLICATION OF POTENT, PROFIBROTIC MOLECULES, TGFΒ AND PDGF.CONTRAVIR PHARMA- CO-ADMINISTRATION OF CLINICAL PHASE DRUG CANDIDATE, FOUND TO BE 100% EFFECTIVE AT PREVENTING FIBROSIS INDUCTION BEYOND BASELINE LEVELS.CONTRAVIR PHARMA- CRV431 AT CLINICALLY RELEVANT CONCENTRATIONS PARTIALLY/COMPLETELY BLOCKED SEVERAL GENETIC & PROTEIN BIOMARKERS OF INFLAMMATION.CONTRAVIR PHARMACEUTICALS INC - CRV431 WAS MORE EFFECTIVE AT PREVENTING FIBROSIS THAN ELAFIBRANOR, A DUAL PPAR Α/Δ AGONIST, AND OBETICHOLIC ACID.CONTRAVIR PHARMACEUTICALS INC - ELAFIBRANOR WAS 62% EFFECTIVE AND OCA WAS 9% EFFECTIVE AT PREVENTING FIBROSIS.  Full Article

Chimerix Says Contravir Pharmaceuticals Intends To Terminate License Agreement
Thursday, 4 Apr 2019 

April 4 (Reuters) - Chimerix Inc ::CHIMERIX -ON APRIL 2 CO RECEIVED NOTIFICATION FROM CONTRAVIR PHARMACEUTICALS OF ITS INTENTION TO TERMINATE LICENSE AGREEMENT BETWEEN CO AND CONTRAVIR.CHIMERIX INC - LICENSE AGREEMENT BY AND BETWEEN COMPANY AND CONTRAVIR, DATED DECEMBER 17, 2014.CHIMERIX INC - TERMINATION OF LICENSE AGREEMENT WILL BE EFFECTIVE ON JUNE 1, 2019.CHIMERIX INC - CONTRAVIR MADE DECISION TO TERMINATE LICENSE AGREEMENT FOLLOWING ITS DECISION TO NO LONGER PURSUE DEVELOPMENT OF CMX157.CHIMERIX INC - UPON EFFECTIVENESS OF TERMINATION OF LICENSE AGREEMENT, COMPANY WILL REACQUIRE ALL WORLDWIDE RIGHTS TO CMX157.  Full Article

Donald E. Garlikov Reports Passive Stake Of 16.57 Percent In Contravir Pharmaceuticals As Of Mar 13, 2019 - SEC Filing
Tuesday, 2 Apr 2019 

April 2 (Reuters) - ContraVir Pharmaceuticals Inc ::DONALD E. GARLIKOV REPORTS A PASSIVE STAKE OF 16.57 PERCENT IN CONTRAVIR PHARMACEUTICALS AS OF MAR 13, 2019 - SEC FILING.  Full Article

Robert Foster Appointed Acting CEO Of Contravir Pharmaceuticals
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - ContraVir Pharmaceuticals Inc ::ROBERT FOSTER APPOINTED ACTING CHIEF EXECUTIVE OFFICER OF CONTRAVIR PHARMACEUTICALS, INC..CONTRAVIR PHARMACEUTICALS INC - APPOINTMENT OF ROBERT FOSTER, AS ITS ACTING CHIEF EXECUTIVE OFFICER, EFFECTIVELY IMMEDIATELY.CONTRAVIR PHARMACEUTICALS INC - FOSTER SUCCEEDS JAMES SAPIRSTEIN AS COMPANY'S CHIEF EXECUTIVE OFFICER.  Full Article